Home Cart Sign in  
Chemical Structure| 1414943-88-6 Chemical Structure| 1414943-88-6

Structure of Atuveciclib Racemate
CAS No.: 1414943-88-6

Chemical Structure| 1414943-88-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Atuveciclib Racemate is the racemate form of Atuveciclib.

Synonyms: BAY-1143572 Racemate; Atuveciclib; BAY-1143572

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Atuveciclib Racemate

CAS No. :1414943-88-6
Formula : C18H18FN5O2S
M.W : 387.43
SMILES Code : N=S(CC1=CC(NC2=NC(C3=CC=C(F)C=C3OC)=NC=N2)=CC=C1)(C)=O
Synonyms :
BAY-1143572 Racemate; Atuveciclib; BAY-1143572
MDL No. :MFCD30502894
InChI Key :ACWKGTGIJRCOOM-UHFFFAOYSA-N
Pubchem ID :71618220

Safety of Atuveciclib Racemate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Atuveciclib Racemate

Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SU-DIPG4 769 nM 5 days To evaluate the anti-tumor effect of Atuveciclib on SU-DIPG4 cells PMC11670739
HSJD-DIPG007 769 nM 5 days To evaluate the anti-tumor effect of Atuveciclib on HSJD-DIPG007 cells PMC11670739
BT245 769 nM 5 days To evaluate the anti-tumor effect of Atuveciclib on BT245 cells PMC11670739
Human nucleus pulposus cells 200 nM 48 hours Atuveciclib significantly suppressed the IL-1β-induced inflaμMatory response, reducing the expression of μMP-3, μMP-13, and ADAMTS5, while increasing the expression of aggrecan and collagen 2. PMC7511812
Rat nucleus pulposus cells 200 nM 48 hours Atuveciclib significantly suppressed the IL-1β-induced inflaμMatory response, reducing the expression of μMP-3, μMP-13, and ADAMTS5, while increasing the expression of aggrecan and collagen 2. PMC7511812
HeLa cells 920 nM 96 hours Evaluate the antiproliferative activity of Atuveciclib against HeLa cells, showing an IC50 of 920 nM PMC5698704
MOLM-13 cells 310 nM 96 hours Evaluate the antiproliferative activity of Atuveciclib against MOLM-13 cells, showing an IC50 of 310 nM PMC5698704
T-PLL cells 0.537 µM to 1.653 µM 48 hours To evaluate the anti-leukemic activity of Atuveciclib on T-PLL cells, the results showed that Atuveciclib exhibited significant anti-leukemic effects in all patient samples. PMC7570784
PBMCs 3.4 ± 0.7 μM 6 days Suppression of HIV-1 NL4.3 replication in PBMCs PMC8052299
J-Lat 9.2 cells 1.7 ± 0.2 μM 24 hours Inhibition of LRA-induced provirus expression PMC8052299
J-Lat 10.6 cells 4.3 ± 0.2 μM 24 hours Inhibition of LRA-induced provirus expression PMC8052299
OM-10.1 cells 1.8 ± 0.09 μM 24 hours Inhibition of TNFα-induced provirus expression PMC8052299

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice BT245 xenograft model Oral 30 mg/kg/day Once daily for 5 days To evaluate the anti-tumor effect of Atuveciclib in the BT245 xenograft model PMC11670739
Rat Intervertebral disk degeneration model Intraperitoneal injection 150 mg/kg single injection Atuveciclib significantly suppressed the progression of intervertebral disk degeneration, reduced ECM degradation, and increased the expression of aggrecan and collagen 2. PMC7511812
Mice MOLM-13 xenograft model Oral 30 mg/kg/dose Once daily for 3 days followed by a 2-day break, for a total of 9 cycles Evaluate the antitumor efficacy of Atuveciclib in the MOLM-13 xenograft model, showing dose-dependent tumor growth inhibition and good tolerability PMC5698704
BALB/c mice Hepatocellular carcinoma model Oral 5 mg/kg, 10 mg/kg Single dose, recorded for 90 minutes Evaluate the efficacy of Atuveciclib in combination with anti-PD-L1 antibody PMC11296019

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02345382 Leukemia Phase 1 Completed - United States, Massachusetts ... More >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New Jersey Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 United States, New York Columbia University Medical Center New York, New York, United States, 10032 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Tennessee Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232 Germany Universitätsklinikum der Johann Wolfgang Goethe Universität Frankfurt, Hessen, Germany, 60596 Medizinische Fakultät Carl Gustav Carus Dresden, Sachsen, Germany, 01307 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.58mL

0.52mL

0.26mL

12.91mL

2.58mL

1.29mL

25.81mL

5.16mL

2.58mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories